Nasal Microbiota Transplant for Staphylococcus aureus Colonization

(NMT Protocol 3 Trial)

Overseen by Aaron M Milstone, MD

Age: < 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Johns Hopkins University

Trial Summary

What is the purpose of this trial?

This protocol aims to evaluate how NMT affects pediatric nasal microbiome diversity following intranasal mupirocin treatment

Research Team

Aaron M Milstone, MD

Principal Investigator

Johns Hopkins University

Eligibility Criteria

This trial is for children who have had a nasal mupirocin treatment to clear staph infections. They should not currently be sick with an infection or have conditions that affect the immune system.

Inclusion Criteria

Infant has had a prior nasal surveillance culture grow S. aureus

My baby was born after more than 25 weeks of pregnancy.

Donor is able to provide informed consent

Exclusion Criteria

Infant is a ward of the State

Donor tests positive on baseline screening test for a respiratory pathogen

Donor is not able to provide written informed consent

Treatment Details

Interventions

• Nasal Microbiota Transplant (NMT) (Microbiome Therapy)

Trial Overview The study tests if Nasal Microbiota Transplant (NMT) can restore the variety of microbes in kids' noses after mupirocin, compared to a placebo group.

Participant Groups

Group I: Single NMT Experimental Treatment 1 Intervention

Swab parent nares then insert swab directly into neonate nares once.

Group II: Repeat NMT Experimental Treatment 1 Intervention

Swab parents nares then insert swab directly into neonate nares multiple times.

Group III: Placebo Placebo Group 1 Intervention

Insert a sterile swab into neonate nares.

Who Is Running the Clinical Trial?

Johns Hopkins University

Lead Sponsor

Trials

2,366

Recruited

15,160,000+